Newer antifungal agents

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 3, 2011, Pages 325-338

  Türel, Özden ^a  

^a Bakirkoy Maternity and Children's Research Hospital   (Turkey)

Author keywords

albaconazole; aminocandin; isavuconazole; ravuconazole

Indexed keywords

ALBACONAZOLE; AMINOCANDIN; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ARYLAMIDINE; BMS 379224; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; HMR 3270; ICOFUNGIPEN; ISAVUCONAZOLE; ISAVUCONAZONIUM; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; RO 0098557; SPK 843; T 2307; UNCLASSIFIED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ASPERGILLOSIS; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTION; CHAGAS DISEASE; CRYPTOCOCCAL MENINGITIS; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; HEADACHE; HUMAN; IN VITRO STUDY; INVASIVE CANDIDIASIS; LEISHMANIASIS; LUNG ASPERGILLOSIS; MAXIMUM PLASMA CONCENTRATION; MUCOCUTANEOUS CANDIDIASIS; MYCOSIS; NAUSEA; NONHUMAN; ONYCHOMYCOSIS; PNEUMOCYSTOSIS; PRURITUS; RASH; REVIEW; RHINITIS; RHINOPHARYNGITIS; TREATMENT PLANNING; TRYPANOSOMIASIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS, INVASIVE; CHILD; CLINICAL TRIALS AS TOPIC; HALF-LIFE; HUMANS; LIPOPEPTIDES; NITRILES; PYRIDINES; QUINAZOLINES; THIAZOLES; TRIAZOLES;

EID: 79952983544     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.163     Document Type: Review

References (107)

1. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J. Antimicrob. Chemother. 61(Suppl. 1), i19-i30 (2008).
2. Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect. Dis. Clin. North Am. 10, 365-400 (1996). (Pubitemid 26248591)
3. Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert. Rev. Anti Infect. Ther. 7(8), 981-988 (2009).
4. Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin. Investig. Drugs. 18(9), 1279-1295 (2009).
5. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. 10(Suppl. 1), 48-66 (2004). (Pubitemid 38379951)
6. Pfaller MA, Messer SA, Boyken L et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol. 46(8), 2568-2572 (2008).
7. Thompson GR 3rd, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 170(5), 291-313 (2010).
8. Odds FC. Drug evaluation: BAL-8557, a novel broad-spectrum triazole antifungal. Curr. Opin. Investig. Drugs. 7, 766-772 (2006). (Pubitemid 44263181)
9. Schmitt-Hoffman A, Roos B, Roehrle M et al. No relevant food effect in man on isavuconazole oral pharmacokinetics preliminary data. Presented at: 48th Annual International Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, USA, 25-28 October 2008.
10. Schmitt-Hoffmann A, Roos B, Maares J et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob. Agents Chemother. 50(1), 286-293 (2006). (Pubitemid 43042934)
11. Schmitt-Hoffmann A, Roos B, Spickermann J et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob. Agents Chemother. 53(11), 4885-4890 (2009).
12. Guinea J, Peláez T, Recio S, Torres- Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob. Agents Chemother. 52(4), 1396-1400 (2008). (Pubitemid 351522004)
13. Yamazaki T, Inagaki Y, Fujii T et al. In vitro activity of isavuconazole against reference fungal strains and 165 clinically isolated yeasts from Japan. Int. J. Antimicrob. Agents. 36(4), 324-331 (2010).
14. Seifert H, Aurbach U, Stefanik D, Cornely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob. Agents Chemother. 51(5), 1818-1821 (2007). (Pubitemid 46744163)
15. Mouton JW, Verweij PE, Warn P et al. In vitro activity of a new triazole BAL4815 against Candida isolates with decreased fluconazole susceptibility. Presented at: Trends in Medical Mycology (TIMM). Berlin, Germany, 23-26 October 2005.
16. Sanglard D, Ischer F, Coste A, Rerrari S. Comparison between isavuconazole (ISA) and other azoles against characterized clinical isolates and yeast model systems. Presented at: 18th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona, Spain, 19-22 April 2008.
17. Thompson GR 3rd, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 53(1), 309-311 (2009).
18. Illnait-Zaragozi MT, Martínez GF, Curfs-Breuker I, Fernández CM, Boekhout T, Meis JF. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob. Agents Chemother. 52(4), 1580-1582 (2008). (Pubitemid 351522042)
19. Guinea J, Hagen F, Peláez T et al. Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain. Med. Mycol. 48(7), 942-948 (2010).
20. Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J. Antimicrob. Chemother. 57, 135-138 (2006). (Pubitemid 43057070)
21. Perkhofer S, Lechner V, Lass-Flörl C; European Committee on Antimicrobial Susceptibility Testing. In vitro activity of isavuconazole against Aspergillus species and Zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility testing. Antimicrob. Agents Chemother. 53(4), 1645-1647 (2009).
22. Gonzalez GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med. Mycol. 47, 71-76 (2009).
23. Ghannoum M, Isham N. Antifungal activity of BAL4815, a novel azole, against dermatophytes. Presented at: Trends in Medical Mycology (TIMM). Berlin, Germany, 23-26 October 2005.
24. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. 45(7), 2151-2153 (2001). (Pubitemid 32591717)
25. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150, 101-115 (2001). (Pubitemid 32623880)
26. Guinea J, Recio S, Escribano P, Peláez T, Gama B, Bouza E. In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. Antimicrob. Agents Chemother. 54, 4012-4015 (2010).
27. Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, impact of immune status on antifungal effect. Antimicrob. Agents Chemother. 53, 3453-3461 (2009).
28. Majithiya J, Sharp A, Parmar A, Denning DW, Warn PA. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic models of disseminated Candida tropicalis and Candida krusei. J. Antimicrob. Chemother. 61, 161-166 (2009).
29. Warn PA, Sharp A, Mosquera J et al. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J. Antimicrob. Chemother. 58, 1198-1207 (2006). (Pubitemid 44884139)
30. Schmitt-Hoffmann A, Roos B, Heep M et al. Single ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob. Agents Chemother. 50, 279-285 (2006). (Pubitemid 43042933)
31. Viljoen JJ, Mitha I, Heep M et al. Efficacy, safety, and tolerability of three different dosing regimens of BAL8557 vs fluconazole in a double-blind, randomized, multicenter trial for the treatment of esophageal candidiasis in immunocompromised adults. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 16-19 December 2005.
32. Schmitt-Hoffman A, Roos B, Sauer J et al. Effect of rifampicin on the pharmacokinetics of BAL4815 at steady state after multiple oral doses of BAL8557 (WSA) and rifampicin. Presented at: 16th Congress of the International Society for Human and Animal Mycology (ISHAM). Paris, France, 25-26 June 2006.
33. Schmitt-Hoffman A, Roos B, Sauer J et al. Effect of BAL8557, a water-soluble azole pro-drug (WSA), on the pharmacokinetics of Sand R-warfarin. Presented at: 16th Congress of the International Society for Human and Animal Mycology (ISHAM). Paris, France, 25-26 June 2006.
34. Schmitt-Hoffman A, Roos B, Sauer J et al. Effect of BAL8557, a water-soluble azole pro-drug (WSA), on the pharmacokinetics of ciclosporin. Presented at: 16th Congress of the International Society for Human and Animal Mycology (ISHAM). Paris, France, 25-26 June 2006.
35. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J. Clin. Microbiol. 44(5), 1782-1787 (2006). (Pubitemid 43726269)
36. González GM, Elizondo M, Ayala J. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. J. Clin. Microbiol. 46(9), 2902-2905 (2008).
37. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46(6), 1723-1727 (2002). (Pubitemid 34535188)
38. St-Germain G, Laverdiére M, Pelletier R et al. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: report on 453 cases between 2003 and 2005. M. Can. J. Infect. Dis. Med. Microbiol. 19(1), 55-62 (2008). (Pubitemid 351547673)
39. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN. In vitro susceptibilities of rare Candida blood stream isolates to ravuconazole and three comparative antifungal agents. Diagn. Microbiol. Infect. Dis. 48(2), 101-195 (2004).
40. Pfaller MA, Messer SA, Boyken L et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. 43(5), 2163-2167 (2005). (Pubitemid 40656221)
41. Yamazumi T, Pfaller MA, Messer SA, Houston A, Hollis RJ, Jones RN. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 44(10), 2883-2886 (2000).
42. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against (2003). Presentation of the activity of new triazoles and caspofungin against a large collection of filamentous fungi. recent clinical isolates of filamentous fungi. J. Clin. Microbiol. 41(8), 3623-3626 (2003). Presentation of the activity of new triazoles and caspofungin against a large collection of filamentous fungi.
43. Pfaller MA, Messer SA, Hollis RJ, Jones RN; SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. 46(4), 1032-1037 (2002). (Pubitemid 34260347)
44. Minassian B, Huczko E, Washo T, Bonner D, Fung-Tomc J. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Clin. Microbiol. Infect. 9(12), 1250-1252 (2003). (Pubitemid 38028881)
45. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Monzon A, Rodriguez-Tudela JL. In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob. Agents Chemother. 49(12), 5136-5138 (2005). (Pubitemid 41778934)
46. Ortoneda M, Capilla J, Javier Pastor F et al. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn. Microbiol. Infect. Dis. 48, 69-71 (2004). (Pubitemid 38167503)
47. González GM, Fothergill AW, Sutton DA, Rinaldi MG, Loebenberg D. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med. Mycol. 43(3), 281-284 (2005). (Pubitemid 40867502)
48. Howard SJ, Webster I, Moore CB et al. Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents. 28(5), 450-453 (2006). (Pubitemid 44740492)
49. Pfaller MA, Messer SA, Boyken L et al. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J. Clin. Microbiol. 42(7), 3137-3141 (2004). (Pubitemid 38938070)
50. Hata K, Kimura J, Miki H, Toyosawa T, Moriyama M, Katsu K. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 40(10), 2243-2247 (1996). (Pubitemid 26328023)
51. Clemons KV, Stevens DA. Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice. Antimicrob. Agents Chemother. 45(12), 3433-3436 (2001). (Pubitemid 33107858)
52. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J. Antimicrob. Chemother. 49(2), 353-357 (2002). (Pubitemid 34162628)
53. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. 44(12), 3381-3388 (2000). (Pubitemid 33009499)
54. Petraitiene R, Petraitis V, Lyman CA et al. Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 48(4), 1188-1196 (2004). (Pubitemid 38405472)
55. Petraitiene R, Petraitis V, Sarafandi A et al. Synergistic activity between ravuconazole and the echinocandin micafungin in treatment of experimental pulmonary aspergillosis. Presented at: 42th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 27-30 September 2002.
56. Meletiadis J, Petraitis V, Petraitiene R et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J. Infect. Dis. 194, 1008-1118 (2006).
57. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47(4), 1193-1199 (2003). (Pubitemid 36368574)
58. Clemons KV, Martinez M, Calderon L, Stevens DA. Efficacy of ravuconazole in treatment of systemic murine histoplasmosis. Antimicrob. Agents Chemother. 46(3), 922-924 (2002). (Pubitemid 34157691)
59. Olsen SJ, Mummaneni V, Rolan P et al. Ravuconazole single ascending oral dose study in healthy subjects. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 17-20 September 2000.
60. Grasela DM, Olsen SJ, Mummaneni V et al. Ravuconazole: multiple ascending oral dose study in healthy subjects. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 17-20 September 2000.
61. Bello A, Russo R, Grasela D et al. Pharmacokinetics of intravenous BMS- 379224 (pro-drug of ravuconazole) in healthy male subjects. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 14-17 September 2003.
62. Marino MR, Mummanei V, Norton J et al. Ravuconazole exposure-response relationship in HIV-patients with oropharyngeal candidiasis. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 16-19 December 2001.
63. Beale M, Queiroz-Telles F, Banhegyi D et al. Randomized, double-blind study of the safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA, 16-19 September 2001.
64. Yan JH, Marino MR, Smith RA, Kanamaluru V, O'Mara EM, Grasela DM. The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers. J. Clin. Pharmacol. 46(2), 193-200 (2006). (Pubitemid 43146450)
65. Gupta AK, Leonardi C, Stoltz RR, Pierce PF. A Phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J. Eur. Acad. Dermatol. 19, 437-443 (2005). (Pubitemid 40946096)
66. Lin P, Mickiene D, Roden MM et al. Pharmacokinetics and safety of ravuconazole for prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, USA (2005) (Abstract A-220).
67. Urbina JA, Payares G, Sanoja C, Lira R, Romanha AJ. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicrob. Agents. 21(1), 27-38 (2003). (Pubitemid 36043972)
68. Ramos G, Cuenca-Estrella M, Monzón A, Rodríguez-Tudela JL. In vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J. Antimicrob. Chemother. 44, 283-286 (1999). (Pubitemid 29389293)
69. Miller JL, Schell WA, Wills EA et al. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob. Agents Chemother. 48, 384-387 (2004). (Pubitemid 38141691)
70. Morera-López Y, Torres-Rodríguez JM, Jiménez-Cabello T, Baró-Tomás T. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med. Mycol. 43(6), 505-510 (2005). (Pubitemid 41700943)
71. Capilla J, Ortoneda M, Pastor FJ, Guarro J. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob. Agents Chemother. 45, 2635-2637 (2001). (Pubitemid 32801923)
72. Gilgado F, Serena C, Cano J, Gene J, Guarro J. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob. Agents Chemother. 50, 4211-4213 (2006). (Pubitemid 44865174)
73. Serena C, Ortoneda M, Capilla J et al. In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization. Antimicrob. Agents Chemother. 47(10), 3161-3164 (2003). (Pubitemid 37229573)
74. Garau M, Pereiro M Jr, del Palacio A. In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds. Antimicrob. Agents Chemother. 47, 2342-2344 (2003). (Pubitemid 36753598)
75. Urbina JA, Lira R, Visbal G et al. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 44, 2498-2502 (2000). (Pubitemid 30650901)
76. Vericat ML, Algueró M, Merlos M, Pérez LL, Araño A, Forn J. UR-9825, a novel broad spectrum triazole for treatment of fungal infections: oral activity in systemic mycoses. In: Final Programme and Abstract Book Trends in Invasive Fungal Infections 4., Barcelona, Spain. Imedex, The Netherlands (1997) (Abstract P-94).
77. González GM, Robledo E, Garza-González E, Elizondo M, González JG. Efficacy of albaconazole against Candida albicans in a vaginitis model. Antimicrob. Agents Chemother. 53, 4540-4541 (2009).
78. Bartroli J, Turmo E, Alguero M et al. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted- 4(3H)- quinazolinones. J. Med. Chem. 41, 1869-1882 (1998). (Pubitemid 28248662)
79. Guedes PM, Urbina JA, de Lana M et al. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob. Agents Chemother. 48(11), 4286-4292 (2004). (Pubitemid 39434888)
80. Capilla J, Yustes C, Mayayo E et al. Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits. Antimicrob. Agents Chemother. 47, 1948-1951 (2003). (Pubitemid 36637819)
81. Izquierdo I, Lurigados C, Perez I et al. First administration into man of UR-9825: a new triazole class of antifungal agent. In: Abstracts of the Sixth Congress of the European Confederation of Medical Mycology Societies (ECMM). Barcelona, Spain (2000) (Abstract P2-004).
82. Bartroli X, Uriach J. A clinical multicenter study comparing efficacy and tolerability between five single oral doses of albaconazole and fluconazole 150 mg single dose in acute vulvovaginal candidiasis. In: Abstracts of the Forty-fifth Interscience Conference on Antimicriobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, USA (2005) (Abstract M-722).
83. Denning DW. Echinocandin antifungal drugs. Lancet 362, 1142-1151 (2003). (Pubitemid 37222342)
84. Andes D, Marchillo K, Lowther J et al. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob. Agents Chemother. 47, 1187-1192 (2003). (Pubitemid 36368573)
85. Isham N, Ghannoum MA. Determination of MICs of aminocandin for Candida spp. and filamentous fungi. J. Clin. Microbiol. 44, 4342-4344 (2006). (Pubitemid 44937061)
86. Laverdiere M, Labbé AC, Restieri C et al. Susceptibility patterns of Candida species recovered from Canadian intensive care units. J. Crit. Care 22, 245-250 (2007). (Pubitemid 47385967)
87. Ghannoum MA, Dutta S, Isham N. The effect of aminocandin compared to caspofungin and micafungin. In: Abstracts of the Sixteenth European Congress of Clinical Microbiology and Infectious Diseases. Nice, France (2006) (Abstract P-746).
88. Warn PA, Sharp A, Morrissey G et al. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole resistant strain of Candida tropicalis. J. Antimicrob. Chemother. 56, 590-593 (2005). (Pubitemid 41264142)
89. Ghannoum MA, Kim HG, Long L. Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazoleresistant candidiasis. J. Antimicrob. Chemother. 59, 556-559 (2007). (Pubitemid 47073466)
90. Brzankalski GE, Najvar LK, Wiederhold NP et al. Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. J. Antimicrob. Chemother. 62, 1094-1100 (2008).
91. Najvar LK, Bocanegra R, Wiederhold NP et al. Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice. Clin. Microbiol. Infect. 4, 595-600 (2008). (Pubitemid 351639075)
92. Warn PA, Sharp A, Morrissey G, Denning DW. Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus. Int. J. Antimicrob. Agents. 35, 146-151 (2010).
93. Sandage B, Cooper G, Najarian N et al. Pharmacokinetics and fungicidal activity of aminocandin (HMR3270), a novel echinocandin in healthy volunteers. In: Abstracts of the Fifteenth European Congress of Clinical Microbiology and Infectious Diseases. European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark (2005) (Abstract P-1115).
94. Kakeya H, Miyazaki Y, Senda H et al. Efficacy of SPK-843, a novel polyene antifungal, in a murine model of systemic cryptococcosis. Antimicrob. Agents Chemother. 52(5), 1871-1872 (2008). (Pubitemid 351614692)
95. Rimaroli C, Bruzzese T. In vitro activity of a new polyene, SPA-S-843, against yeasts. Antimicrob. Agents Chemother. 42(11), 3012-3013 (1998). (Pubitemid 28501244)
96. Kakeya H, Miyazaki Y, Senda H et al. Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis. Antimicrob. Agents Chemother. 52, 1868-1870 (2008). (Pubitemid 351614691)
97. Lanteri CA, Trumpower BL, Tidwell RR, Meshnick SR. DB75, a novel trypanocidal agent, disrupts mitochondrial function in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 48, 3968-3974 (2004). (Pubitemid 39304629)
98. Mitsuyama J, Nomura N, Hashimoto K et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob. Agents Chemother. 52(4), 1318-1324 (2008). (Pubitemid 351521993)
99. Hasenoehrl A, Galic T, Ergovic G et al. In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans. Antimicrob. Agents Chemother. 50(9), 3011-3018 (2006). (Pubitemid 44396406)
100. Petraitiene R, Petraitis V, Kelaher AM et al. Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 49(5), 2084-2092 (2005). (Pubitemid 40631627)
101. Kitamura A, Someya K, Hata M, Nakajima R, Takemura M. Discovery of a smallmolecule inhibitor of {b}-1,6-glucan synthesis. Antimicrob. Agents Chemother. 53(2), 670-677 (2009).
102. Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (Study P05520AM1) http://clinicaltrials.gov/ct2/show/ NCT010 75984-term=NCT01075984&rank=1
103. Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy http://clinicaltrials.gov/ct2/show/NCT004 13439-term=NCT00413439&rank=1
104. Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis http://clinicaltrials.gov/ct2/show/NCT00412893-term=NCT00412893&rank=1
105. Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections http://clinicaltrials.gov/ct2/show/NCT004 13218-term=NCT00444366&rank=1
106. Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi http://clinicaltrials.gov/ct2/show/NCT006 34049-term= NCT00634049&rank=1
107. Eisai - DNDi Chagas R&D Collaboration www.ifpma.org/index.php-id=3648